With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.
Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.
Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.
Intercept has been the presumed leader in the NASH drug race, but 19 deaths in current Ocaliva patients pose a threat to those plans.
The breast cancer med Ibrance has been a shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to lift the whole company.
Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.
Buried in OTC remedies like laxatives, fiber and probiotics? That's the question in Allergan and Ironwood's latest Linzess ads.
After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing…
After years of being recruited, pro athlete Deion Sanders is doing some recruiting of his own—for Botox.
AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.